Navigation Links
TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Date:12/6/2012

PHOENIX, Ariz. Dec. 6, 2012 Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

The study is published by the journal Molecular Cancer Therapeutics and is currently available online.

By sequencing, or spelling out, the billions of letters contained in the genomes of 14 tumors from ethnically diverse metastatic TNBC patients, TGen and US Oncology Research investigators found recurring significant mutations and other changes in more than a dozen genes. In addition, the investigators identified mutations previously unseen in metastatic TNBC and took the sequencing data into account in selection of therapeutic protocols specific to each patient's genetic profile.

"This study stands as a one-of-a-kind effort that has already led to potentially beneficial clinical trials, and sets the stage for future investigations," said Dr. John Carpten, Ph.D., TGen's Deputy Director of Basic Science and Director of TGen's Integrated Cancer Genomics Division, and the study's senior author.

The most frequently mutated gene among the tumors (seven of 14) was the TP53 tumor suppressor, and aberrations were observed in additional tumor suppressor genes including CTNNA1, which was detected in two of six African American patients (who typically have more aggressive and treatment-resistant disease). Alterations were also seen in the ERBB4 gene, known to be involved in mammary-gland maturation during pregnancy and lactation, but not previously linked to metastatic TNBC.

The study included an "outlier analysis," which assessed expression patterns for each tumor when compared against the other tumors examined in the study. Specific cancer genes overexpressed among tumors in the study's cohort included: ALK, AR, ARAF, BRAF, FGFR2, GLI1, GLI2, HRA
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. ESMO 2012 Congress: A path for medical oncology innovations
2. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
3. ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments
4. Protein injection points to muscular dystrophy treatment
5. Possible new treatment for Ewing sarcoma
6. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
7. Notre Dame research could improve sustainability and cost effectiveness of wastewater treatment
8. Bringing measuring accuracy to radical treatment
9. Superbug MRSA identified in US wastewater treatment plants
10. Scientists unravel resistance to breast cancer treatment
11. FDA Grants Meridian Laboratories Pre-Ind Meeting for Captisol-Enabled Docetaxel in the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... New Rochelle, NY, December 2, 2010 For ... addressed at the highest level of government. With the ... the U.S. Department of Health and Human Services has ... - and supporting breastfeeding is prominent among them. ...
... scientists at the University of Leicester have recorded stunning ... European Space Agency satellite instruments have been observing ... points in space. Leicester scientists have used ... images of a snow-bound UK from observations on November ...
... of Chicago Medical Center is designed to offer surgeons ... new molecular and mechanical solutions to three age-old problems: ... between blood vessels), improving tissue healing after surgery and ... The conference, "Solving the most challenging surgical ...
Cached Biology News:New public health goals tackle obstacles to breastfeeding success 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2Conference goals include better surgery and better surgeons 2Conference goals include better surgery and better surgeons 3
(Date:8/28/2015)... ... ... of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the cuvette ... in a lab coat and Large Marge have been posted on the company’s Facebook page ... is proud to be the only cuvette manufacturer is the world that has an online ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... an explanation as to where and how North Sea oil ... be the first step on the way to developing improved ... from Danish oil fields. , A research group at the ... of Copenhagen has investigated drill cores collected from North Sea ...
... Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ... notice from NYSE Amex LLC (the "Exchange") that the ... accepted by the Exchange and the Company has been ... compliance with the continued listing standards of the Exchange.As ...
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
Cached Biology Technology:New Danish research shows how oil gets stuck underground 2Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: